Prescribe SGLT2 inhibitors, GLP-1 receptor agonists ‘as early as possible’ for CV benefit

A meta-analysis of eight cardiovascular outcomes trials indicates that adults with type 2 diabetes derive cardiovascular benefit from SGLT2 inhibitors and GLP-1 receptor agonists regardless of concurrent insulin use. Researchers found that while baseline insulin use was associated with a higher likelihood of major adverse CV events, the protective effects of these newer drug classes remained significant. Consequently, experts recommend prescribing these therapies as early as possible in the disease course to maximize cardiac protection.